Researchers have identified a previously overlooked mechanism of brain cell death that plays a major role in Alzheimer's disease and frontotemporal dementia, potentially leading to new treatments.
New Delhi, India Jul 6, 2026 ALN: Scientists have identified evidence of a previously unknown process that may explain how brain cells die in Alzheimer's disease and frontotemporal dementia (FTD). The discovery, centered on a mechanism known as karyoptosis, could point researchers toward new ways to slow the progression of these devastating conditions.
Many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and FTD, are marked by the buildup of harmful proteins inside neurons. Over time, these nerve cells die, contributing to memory loss and other symptoms. Although scientists have long known about several forms of cell death, including apoptosis, those mechanisms have never fully explained the extensive neuron loss seen in these disorders.
Now, researchers from King's College London, working with the UK Dementia Research Institute and supported in part by Alzheimer's Research UK, have identified karyoptosis as a potential missing link connecting toxic protein accumulation to the death of brain cells.
Karyoptosis refers to a series of chemical reactions set in motion when toxic proteins accumulate inside a cell. As the process unfolds, the cell's nucleus, which contains its genetic material, gradually shrivels before ultimately breaking apart. This mechanism is particularly concerning because it suggests that the accumulation of toxic proteins is not merely a symptom of neurodegeneration but may actively drive the cell death process.
The findings, published in Nature Communications, are based on an analysis of 3,000 brain cells collected from 28 people with either FTD or end-stage Alzheimer's disease. Using computational algorithms, the researchers identified different forms of cell death occurring within the tissue. This comprehensive analysis is significant as it underscores the complexity of neurodegenerative diseases and the need for multifaceted approaches to treatment.
They found signs of karyoptosis in 35 percent of cells from the frontal cortex of people with Alzheimer's disease, compared with just 15 percent of cells from older adults. This stark difference highlights the potential role of karyoptosis in the pathology of Alzheimer's and raises questions about whether targeting this process could mitigate the effects of the disease.
"This study is the culmination of a 10-year journey at King's, from when we first identified karyoptosis in a relatively rare disease to discovering that it is a common feature of dementias which affect millions of people," said Dr. Manolis Fanto, Reader in Functional Genomics at King's College London. This statement reflects the long-term commitment of researchers to unravel the complexities of neurodegenerative diseases and their implications for public .
The researchers also uncovered a key molecular pathway that appears to control karyoptosis. They found that forcing proteins inside neurons to clump together, a hallmark of many neurodegenerative diseases, can trigger this destructive process. This finding is particularly relevant as it links the physical properties of proteins to cellular outcomes, suggesting that interventions aimed at preventing protein aggregation could have therapeutic potential.
According to the study, the buildup of toxic proteins destabilizes the outer membrane of the nucleus, causing it to shrink and eventually disintegrate. This insight into the mechanics of karyoptosis provides a clearer picture of how cellular structures are compromised in neurodegenerative diseases and may guide future research into protective strategies.
The team then investigated proteins known as kinases, which act as molecular switches in this pathway. In laboratory experiments using rat neurons, blocking these switches reduced markers associated with karyoptosis. In particular, the interaction between the kinase p38 MAP kinase and the protein LaminB1 emerged as a promising target for slowing or preventing the breakdown of the nucleus. This finding is crucial as it establishes a potential intervention point for therapeutic development.
The researchers believe this pathway could eventually lead to therapies that reduce brain cell loss in dementia. Their next goal is to develop ways to selectively target the interaction between p38 MAP kinase and LaminB1 in humans. This step is essential for translating laboratory findings into clinical applications, which is often a significant challenge in biomedical research.
"By specifically targeting the interaction between p38 MAP kinase and LaminB1 we may slow down the process of cell death, buying time for more pinpointed therapies against specific neurodegenerative diseases," said Dr. Fanto. This statement underscores the potential for karyoptosis-targeted therapies to not only slow disease progression but also to enhance the effectiveness of existing treatments.
"The death and loss of cells in the brain drives many symptoms experienced by people living with dementia. Our study uncovers a new series of chemical events which can coordinate cell death in brain cells. We have started to lay out the road map of how karyoptosis works, and I'm excited to see future breakthroughs this may drive in the dementia research community and beyond," said Dr. Rebecca Casterton, Senior Researcher at the UK Dementia Research Institute at King's and first author on the paper. This sentiment reflects a growing optimism within the scientific community regarding the potential for novel therapeutic strategies.
Dr. Sara Rodrigues, Senior Research Manager at Alzheimer's Research UK, added, "The identification of karyoptosis is a crucial step towards finding targets for treatments that could stop or slow cell loss. It could help widen the window for therapies that tackle the underlying causes of disease, bringing us closer to a cure for dementia." This perspective emphasizes the importance of understanding the fundamental biological processes involved in neurodegeneration as a pathway to developing effective treatments.
The study, "Karyoptosis mediates cell death and neurodegeneration upon proteotoxic stress," was published in Nature Communications. The publication of this research in a reputable scientific journal highlights its significance and potential impact on the field of dementia research.
The research was primarily funded by Alzheimer's Research UK and the Biotechnology and Biological Sciences Research Council International Partnership. Additional support came from a studentship provided by the UK Medical Research Council and the UK Dementia Research Institute. This funding underscores the collaborative nature of scientific research and the importance of investment in understanding complex diseases like Alzheimer's and FTD.
To learn more about the latest developments in Diseases & Conditions, stay updated with our exclusive reports and analyses on AiLensNews.
